US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nasus Pharma Ltd.

3.55

-0.3300-8.51%

Volume:4K

Turnover:14.79K

Market Cap:41.74M

PE:-3.32

High:3.57

Open:3.47

Low:3.17

Close:3.88

52wk High:9.50

52wk Low:1.98

Shares:11.76M

Float Shares:6.21M

Volume Ratio:0.53

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.0691

EPS(LYR):-0.7311

ROE:-316.04%

ROA:-96.73%

PB:3.80

PE(LYR):-4.86

Loading ...

Overview Company News Filings

Nasus Pharma to present at Zacks Life Sciences Investor Forum

Nasus Pharma CEO Dan Benjamin Teleman acquires 6,550 shares for $20,305

Nasus Pharma plans first-in-human PK trial of intranasal ondansetron in Q3 2026

Nasus Pharma - to Initiate First-in-Human Pk Study of Ns003 in Q3 2026

THOMSON REUTERS

Nasus Pharma Announces Positive Results From Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (Ns003)

THOMSON REUTERS

Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)

Nasus Pharma hosts virtual KOL event on NS002 intranasal epinephrine for anaphylaxis

Nasus Pharma CFO to attend Market Movers Investor Summit for 1x1 meetings

Nasus Pharma CEO Dan Benjamin Teleman buys 2,900 shares for $10,904

Nasus Pharma’s CEO Makes Bold Move With Fresh Insider Buy

Nasus Pharma CEO Dan Benjamin Teleman buys USD 0.03 million shares

Nasus Pharma director David Silberman files initial beneficial ownership statement

Nasus Pharma files Form 3 as director Ronnie Hershman reports beneficial ownership

Nasus Pharma director Sharon Shacham files initial beneficial ownership statement

Nasus Pharma files Form 3 for founder, Chief Development Officer Dalia Megiddo

Nasus Pharma files Form 3 as director Israel Isaac reports beneficial ownership

Nasus Pharma Is Maintained at Market Outperform by Citizens

Nasus Pharma price target lowered to $18 from $19 at Citizens

Nasus Pharma advances NS002 to pivotal study following Phase 2 results

Nasus Pharma FY2025 net loss widens 282% to $5.9 million; revenue records no revenue

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/NSRX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NSRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","market":"US","secType":"STK","nameCN":"Nasus Pharma Ltd.","latestPrice":3.55,"timestamp":1788984000000,"preClose":3.88,"halted":0,"volume":4443,"delay":0,"changeRate":-0.0850515463917526,"floatShares":6214000,"shares":11758900,"eps":-1.06915,"marketStatus":"Pre-Mkt","change":-0.33,"latestTime":"09-10 04:48:56 EDT","open":3.47,"high":3.565,"low":3.17,"amount":14792.999601,"amplitude":0.101804,"askPrice":4.02,"askSize":9,"bidPrice":2.76,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-1.06915,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789047000000},"marketStatusCode":1,"adr":0,"listingDate":1755057600000,"exchange":"AMEX","adjPreClose":3.55,"postHourTrading":{"tag":"盘后","latestPrice":3.55,"preClose":3.55,"latestTime":"19:30 EDT","volume":7,"amount":24.59,"timestamp":1788996607321,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5267463440993931},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","floatShares":6214000,"roa":"-96.73%","roe":"-316.04%","lyrEps":-0.731074,"volumeRatio":0.5267463440993931,"shares":11758900,"dividePrice":0,"high":3.565,"amplitude":0.101804,"preClose":3.88,"low":3.17,"week52Low":1.98,"pbRate":"3.80","week52High":9.5,"institutionHeld":0,"latestPrice":3.55,"committee":0.834862,"eps":-1.06915,"divideRate":0,"volume":4443,"delay":0,"ttmEps":-1.06915,"open":3.47,"prevYearClose":9.15,"prevWeekClose":3.735,"prevMonthClose":4.084,"prevQuarterClose":3.5,"fiveDayClose":3.825,"twentyDayClose":3.31,"sixtyDayClose":2.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NSRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NSRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NSRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1766116800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NSRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NSRX","date":"2026-09-09","current":-3.320395,"percent":0.970037,"low":-51.389177,"twenty":-44.647674,"median":-28.389112,"eighty":-6.001389,"high":-4.019591,"avg":-24.780159,"sd":17.640607,"marketCap":45449575},"quantilePoints":[{"date":"2025-08-15","current":-47.343663,"twenty":-48.284655,"median":-47.931783,"eighty":-47.578911,"marketCap":72530491},{"date":"2025-08-22","current":-50.265593,"twenty":-50.691372,"median":-49.082873,"eighty":-48.024103,"marketCap":77006889},{"date":"2025-08-29","current":-47.604473,"twenty":-50.029049,"median":-48.047994,"eighty":-47.509856,"marketCap":72930053},{"date":"2025-09-05","current":-47.370886,"twenty":-49.082873,"median":-47.841017,"eighty":-47.486202,"marketCap":72572198},{"date":"2025-09-12","current":-48.136697,"twenty":-48.519903,"median":-47.66361,"eighty":-47.343663,"marketCap":73745420},{"date":"2025-09-19","current":-47.384488,"twenty":-48.195834,"median":-47.722745,"eighty":-47.36793,"marketCap":72593035},{"date":"2025-09-26","current":-47.604473,"twenty":-48.136697,"median":-47.604473,"eighty":-47.343663,"marketCap":72930053},{"date":"2025-10-03","current":-36.900859,"twenty":-48.077561,"median":-47.51577,"eighty":-47.308794,"marketCap":56532116},{"date":"2025-10-10","current":-45.830394,"twenty":-48.047993,"median":-47.384488,"eighty":-45.830394,"marketCap":70212163},{"date":"2025-10-17","current":-46.835706,"twenty":-47.900153,"median":-47.36793,"eighty":-45.534713,"marketCap":71752301},{"date":"2025-10-24","current":-44.943354,"twenty":-47.900153,"median":-47.314116,"eighty":-44.943354,"marketCap":68853218},{"date":"2025-10-31","current":-46.007802,"twenty":-47.900153,"median":-47.308794,"eighty":-45.239034,"marketCap":70483952},{"date":"2025-11-07","current":-44.647674,"twenty":-47.781881,"median":-47.308794,"eighty":-44.943354,"marketCap":68400236},{"date":"2025-11-14","current":-46.717433,"twenty":-47.722745,"median":-47.22009,"eighty":-44.647674,"marketCap":71571108},{"date":"2025-11-21","current":-41.395195,"twenty":-47.722745,"median":-46.835706,"eighty":-44.351994,"marketCap":63417438},{"date":"2025-11-28","current":-41.395195,"twenty":-47.675437,"median":-46.717433,"eighty":-43.654189,"marketCap":63417438},{"date":"2025-12-05","current":-40.508154,"twenty":-47.6163,"median":-46.155642,"eighty":-42.826285,"marketCap":62058492},{"date":"2025-12-12","current":-38.438395,"twenty":-47.604473,"median":-45.830394,"eighty":-41.395195,"marketCap":58887621},{"date":"2025-12-19","current":-37.669627,"twenty":-47.557164,"median":-45.682553,"eighty":-41.383368,"marketCap":57709868},{"date":"2025-12-26","current":-44.351994,"twenty":-47.509856,"median":-45.298465,"eighty":-41.395195,"marketCap":67947255},{"date":"2026-01-02","current":-43.332802,"twenty":-47.445516,"median":-44.987706,"eighty":-41.359713,"marketCap":82895651},{"date":"2026-01-09","current":-33.62436,"twenty":-47.384488,"median":-44.884218,"eighty":-40.236129,"marketCap":64323401},{"date":"2026-01-16","current":-33.62436,"twenty":-47.379047,"median":-44.647674,"eighty":-40.035066,"marketCap":64323401},{"date":"2026-01-23","current":-31.392839,"twenty":-47.370295,"median":-44.529402,"eighty":-38.570149,"marketCap":60054501},{"date":"2026-01-30","current":-26.473264,"twenty":-47.36793,"median":-44.351994,"eighty":-37.823381,"marketCap":50643354},{"date":"2026-02-06","current":-27.467787,"twenty":-47.363077,"median":-44.351994,"eighty":-35.774424,"marketCap":52545877},{"date":"2026-02-13","current":-34.411045,"twenty":-47.337754,"median":-43.81977,"eighty":-34.753161,"marketCap":65828330},{"date":"2026-02-20","current":-30.724148,"twenty":-47.314116,"median":-43.332802,"eighty":-34.411045,"marketCap":58775295},{"date":"2026-02-27","current":-31.33863,"twenty":-47.308794,"median":-42.873594,"eighty":-33.62436,"marketCap":59950800},{"date":"2026-03-06","current":-30.662699,"twenty":-47.308794,"median":-41.857638,"eighty":-33.151251,"marketCap":58657744},{"date":"2026-03-13","current":-28.389112,"twenty":-47.308794,"median":-41.483899,"eighty":-32.108896,"marketCap":54308372},{"date":"2026-03-20","current":-15.239177,"twenty":-47.308794,"median":-41.395195,"eighty":-31.096524,"marketCap":29152546},{"date":"2026-03-27","current":-4.817647,"twenty":-47.249657,"median":-41.365627,"eighty":-30.724148,"marketCap":28212141},{"date":"2026-04-02","current":-5.099481,"twenty":-47.249657,"median":-40.41945,"eighty":-29.587069,"marketCap":29862560},{"date":"2026-04-10","current":-4.639528,"twenty":-47.202349,"median":-40.212475,"eighty":-29.052754,"marketCap":27169074},{"date":"2026-04-17","current":-4.499542,"twenty":-47.048596,"median":-40.212475,"eighty":-28.102929,"marketCap":26349318},{"date":"2026-04-24","current":-6.799308,"twenty":-46.871188,"median":-39.325435,"eighty":-27.041563,"marketCap":39816747},{"date":"2026-05-01","current":-5.39945,"twenty":-46.741088,"median":-38.438986,"eighty":-25.76289,"marketCap":31619181},{"date":"2026-05-08","current":-6.77931,"twenty":-46.717433,"median":-38.438395,"eighty":-18.667992,"marketCap":39699639},{"date":"2026-05-15","current":-5.939395,"twenty":-46.670125,"median":-36.896469,"eighty":-15.349784,"marketCap":34781099},{"date":"2026-05-22","current":-5.739416,"twenty":-46.374445,"median":-36.254495,"eighty":-7.119275,"marketCap":33610018},{"date":"2026-05-29","current":-6.399349,"twenty":-46.126074,"median":-35.850198,"eighty":-6.399349,"marketCap":37474585},{"date":"2026-06-05","current":-6.47934,"twenty":-46.007802,"median":-35.518691,"eighty":-6.399349,"marketCap":37943017},{"date":"2026-06-12","current":-6.339355,"twenty":-45.901357,"median":-34.571052,"eighty":-6.29136,"marketCap":37123261},{"date":"2026-06-18","current":-6.159373,"twenty":-45.830394,"median":-34.411045,"eighty":-6.175371,"marketCap":36069288},{"date":"2026-06-26","current":-6.599328,"twenty":-45.830394,"median":-33.62436,"eighty":-6.175371,"marketCap":38645666},{"date":"2026-07-02","current":-7.029284,"twenty":-45.771258,"median":-33.505965,"eighty":-6.207368,"marketCap":41163490},{"date":"2026-07-10","current":-6.019387,"twenty":-45.49935,"median":-32.81339,"eighty":-6.167372,"marketCap":35249532},{"date":"2026-07-17","current":-6.139375,"twenty":-45.334124,"median":-32.21535,"eighty":-6.139375,"marketCap":35952180},{"date":"2026-07-24","current":-6.18537,"twenty":-45.191725,"median":-31.392839,"eighty":-6.099379,"marketCap":36221529},{"date":"2026-07-31","current":-6.359353,"twenty":-45.00249,"median":-31.096524,"eighty":-6.099379,"marketCap":37240369},{"date":"2026-08-07","current":-6.77931,"twenty":-44.972922,"median":-30.724148,"eighty":-6.099379,"marketCap":39699639},{"date":"2026-08-14","current":-6.399349,"twenty":-44.943354,"median":-30.662699,"eighty":-6.099379,"marketCap":37474585},{"date":"2026-08-21","current":-4.275233,"twenty":-44.884218,"median":-29.56931,"eighty":-6.079381,"marketCap":45086610},{"date":"2026-08-28","current":-4.552846,"twenty":-44.798471,"median":-29.220042,"eighty":-6.059383,"marketCap":48014312},{"date":"2026-09-04","current":-4.164188,"twenty":-44.647674,"median":-28.450561,"eighty":-6.019387,"marketCap":43915530},{"date":"2026-09-09","current":-4.309651,"twenty":-44.647674,"median":-28.389112,"eighty":-6.001389,"marketCap":45449575}],"updateTime":1789030136952},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NSRX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645241870","title":"Nasus Pharma to present at Zacks Life Sciences Investor Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2645241870","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645241870?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:03","pubTimestamp":1782129826,"startTime":"0","endTime":"0","summary":"Nasus Pharma will present at the Zacks Life Sciences Investor Forum on June 24, 2026, 11:00-11:30 a.m. ET.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL9y3wgP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014021.USD","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4007","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014039.USD","BK4112","IE00B64PRP62.GBP","LU2095319765.USD","IE00BN0W2W23.USD","BK4585","IE00BN0W2T93.GBP","NSRX","BK4588","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645702186","title":"Nasus Pharma CEO Dan Benjamin Teleman acquires 6,550 shares for $20,305","url":"https://stock-news.laohu8.com/highlight/detail?id=2645702186","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645702186?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:13","pubTimestamp":1782126798,"startTime":"0","endTime":"0","summary":"Nasus Pharma CEO Dan Benjamin Teleman bought 6,550 ordinary shares at USD 3.1 each, a Form 4 filing shows.Teleman reported 163,541 ordinary shares beneficially owned following the purchase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL98bHMv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nasus Pharma CEO Dan Benjamin Teleman acquires 6,550 shares for $20,305","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642467364","title":"Nasus Pharma plans first-in-human PK trial of intranasal ondansetron in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642467364","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642467364?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:02","pubTimestamp":1781006538,"startTime":"0","endTime":"0","summary":"Nasus Pharma reported positive preclinical pharmacokinetic and safety results for NS003, its intranasal ondansetron powder for nausea and vomiting.Results have already been presented, supporting a comparable drug exposure profile to intravenous ondansetron in an animal study.A separate toxicology study showed a favorable safety profile, with no adverse effects observed at higher dosing.The program is slated to move into a first-in-human pharmacokinetic study in the third quarter of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL5T03MZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","NSRX","LU2210150020.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014005.SGD","SG9999014039.USD","BK4112","BK4588","BK4585","SG9999014013.SGD","BK4007","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014021.USD","LU0314104364.USD","NDAQ","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642675574","title":"Nasus Pharma - to Initiate First-in-Human Pk Study of Ns003 in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642675574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642675574?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:00","pubTimestamp":1781006404,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUA20QPYC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642048462","title":"Nasus Pharma Announces Positive Results From Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (Ns003)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642048462","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642048462?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:00","pubTimestamp":1781006404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUA20QPYC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642467609","title":"Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642467609","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642467609?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:00","pubTimestamp":1781006400,"startTime":"0","endTime":"0","summary":"Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Profile to Intravenous Ondansetron in Animal Study;Program to Advance to First-in-Human PK Study in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/09/3308784/0/en/Nasus-Pharma-Announces-Positive-Results-from-Preclinical-Pharmacokinetic-and-Safety-Study-of-Intranasal-Ondansetron-NS003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4123","BK4520","AUC","BK4588","BK4516","X","NSRX","BK4007","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640895949","title":"Nasus Pharma hosts virtual KOL event on NS002 intranasal epinephrine for anaphylaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2640895949","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640895949?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315248,"startTime":"0","endTime":"0","summary":"Nasus Pharma will host a virtual KOL event on June 10, 2026 at 8:00 AM ET focused on anaphylaxis treatment.Management plans to highlight NS002, an intranasal epinephrine powder candidate, with discussion of Phase 2 results versus EpiPen injection.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL6nncK1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4112","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","LU2095319765.USD","IE00BN0W2V16.EUR","SG9999014039.USD","NDAQ","NSRX","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU0314104364.USD","BK4588","IE00BN0W2W23.USD","BK4007","LU2210149790.SGD","SG9999014005.SGD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632840617","title":"Nasus Pharma CFO to attend Market Movers Investor Summit for 1x1 meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2632840617","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632840617?lang=en_us&edition=fundamental","pubTime":"2026-05-01 21:14","pubTimestamp":1777641257,"startTime":"0","endTime":"0","summary":"Nasus Pharma management will participate in Market Movers Investor Summit on May 5, 2026, in New York.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL89CGG0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","BK4588","IE00BN0W2T93.GBP","SG9999014021.USD","LU2210149790.SGD","SG9999014005.SGD","NDAQ","LU2095319765.USD","LU0314104364.USD","IE00B64PRP62.GBP","BK4007","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","NSRX","SG9999014013.SGD","SG9999014039.USD","BK4112","LU2210150020.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629070630","title":"Nasus Pharma CEO Dan Benjamin Teleman buys 2,900 shares for $10,904","url":"https://stock-news.laohu8.com/highlight/detail?id=2629070630","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629070630?lang=en_us&edition=fundamental","pubTime":"2026-04-23 09:44","pubTimestamp":1776908689,"startTime":"0","endTime":"0","summary":"Nasus Pharma CEO Dan Benjamin Teleman reported purchase of 2,900 ordinary shares at USD 3.76.Beneficial ownership rose to 156,991 ordinary shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDLxCxK0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nasus Pharma CEO Dan Benjamin Teleman buys 2,900 shares for $10,904","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624291415","title":"Nasus Pharma’s CEO Makes Bold Move With Fresh Insider Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2624291415","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624291415?lang=en_us&edition=fundamental","pubTime":"2026-04-02 10:07","pubTimestamp":1775095637,"startTime":"0","endTime":"0","summary":"New insider activity at Nasus Pharma Ltd. ( ($NSRX) ) has taken place on April 1, 2026. Chief Executive Officer Dan Benjamin Teleman has signaled c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/nasus-pharmas-ceo-makes-bold-move-with-fresh-insider-buy-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/nasus-pharmas-ceo-makes-bold-move-with-fresh-insider-buy-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590027","title":"Nasus Pharma CEO Dan Benjamin Teleman buys USD 0.03 million shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590027","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590027?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:32","pubTimestamp":1775043131,"startTime":"0","endTime":"0","summary":"Nasus Pharma CEO Dan Benjamin Teleman bought 15,000 ordinary shares at USD 2.04.Teleman’s direct holding increased to 21,246 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL39bXHX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nasus Pharma CEO Dan Benjamin Teleman buys USD 0.03 million shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622780103","title":"Nasus Pharma director David Silberman files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2622780103","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622780103?lang=en_us&edition=fundamental","pubTime":"2026-03-28 08:57","pubTimestamp":1774659453,"startTime":"0","endTime":"0","summary":"Nasus Pharma director David Silberman filed an initial Form 3 statement of beneficial ownership.The filing reported a direct holding of options to buy 10,000 ordinary shares.The exercise price was USD 5.38 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDLc4rXGC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622058801","title":"Nasus Pharma files Form 3 as director Ronnie Hershman reports beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2622058801","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622058801?lang=en_us&edition=fundamental","pubTime":"2026-03-28 08:57","pubTimestamp":1774659444,"startTime":"0","endTime":"0","summary":"Nasus Pharma director Ronnie Hershman filed an initial Form 3 disclosing indirect ownership of 1,338,463 ordinary shares.The filing also reported vested share options for 63,017 ordinary shares at an exercise price of USD 4.30.It also listed warrants for 17,970 ordinary shares held indirectly at an exercise price of USD 6.53.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL3PGGYl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622801055","title":"Nasus Pharma director Sharon Shacham files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2622801055","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622801055?lang=en_us&edition=fundamental","pubTime":"2026-03-28 08:57","pubTimestamp":1774659443,"startTime":"0","endTime":"0","summary":"Nasus Pharma director Sharon Shacham filed an initial Form 3 statement of beneficial ownership.The filing reported a direct share option for 10,000 ordinary shares with an exercise price of USD 5.38.The option was exercisable from March 11, 2026 and expires on December 11, 2035.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL12hgh6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622801034","title":"Nasus Pharma files Form 3 for founder, Chief Development Officer Dalia Megiddo","url":"https://stock-news.laohu8.com/highlight/detail?id=2622801034","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622801034?lang=en_us&edition=fundamental","pubTime":"2026-03-28 08:57","pubTimestamp":1774659441,"startTime":"0","endTime":"0","summary":"Nasus Pharma filed an initial beneficial ownership statement for founder Dalia Megiddo, its chief development officer and a director.Megiddo reported direct ownership of 1,888,873 ordinary shares.She also reported indirect ownership of 5,195 ordinary shares.The filing listed March 18, 2026 as the event date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL4ZmZ0M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622032801","title":"Nasus Pharma files Form 3 as director Israel Isaac reports beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2622032801","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622032801?lang=en_us&edition=fundamental","pubTime":"2026-03-28 08:57","pubTimestamp":1774659439,"startTime":"0","endTime":"0","summary":"Nasus Pharma director Israel Isaac filed an initial Form 3 disclosure.The filing lists a direct share option for 10,000 ordinary shares with an exercise price of USD 5.38.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL59QDbj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622868003","title":"Nasus Pharma Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2622868003","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622868003?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:16","pubTimestamp":1774530960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NSRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2026 09:16 ET (13:16 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622855182","title":"Nasus Pharma price target lowered to $18 from $19 at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2622855182","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622855182?lang=en_us&edition=fundamental","pubTime":"2026-03-26 17:55","pubTimestamp":1774518909,"startTime":"0","endTime":"0","summary":"Citizens lowered the firm’s price target on Nasus Pharma (NSRX) to $18 from $19 and keeps an Outperform rating on the shares. Following the quarter...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nasus-pharma-price-target-lowered-to-18-from-19-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nasus-pharma-price-target-lowered-to-18-from-19-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622719460","title":"Nasus Pharma advances NS002 to pivotal study following Phase 2 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622719460","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622719460?lang=en_us&edition=fundamental","pubTime":"2026-03-25 21:37","pubTimestamp":1774445878,"startTime":"0","endTime":"0","summary":"Nasus Pharma (NSRX) provided a business update highlighting recent Phase 2 results for NS002, its intranasal powder epinephrine product candidate f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nasus-pharma-advances-ns002-to-pivotal-study-following-phase-2-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nasus-pharma-advances-ns002-to-pivotal-study-following-phase-2-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622507964","title":"Nasus Pharma FY2025 net loss widens 282% to $5.9 million; revenue records no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2622507964","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622507964?lang=en_us&edition=fundamental","pubTime":"2026-03-25 21:14","pubTimestamp":1774444499,"startTime":"0","endTime":"0","summary":"FY2025 operating loss climbed to $4.9 million, up 355%.FY2025 research and development expenses jumped to $2,237,000, up 568% on higher NS002 development spending, including higher payroll, share-based compensation and third-party clinical research expenses.FY2025 general and administrative expenses rose to $2,667,000, up 259% on higher public company costs, higher payroll and payroll-related expenses, higher business consultant expenses and higher share-based compensation.Management said it expected existing cash and cash equivalents to be sufficient to fund operations through the second quarter of FY2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief v","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL4XZdYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":51,"code":"91000000","status":"200"}]}}